Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 5 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 216.00 | |
| 25 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 716.00 |
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C10H12FNO3
Numero CAS:
Peso molecolare:
213.21
UNSPSC Code:
12352200
NACRES:
NA.77
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiNome del prodotto
AFMT racemate, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
OC1=CC=C(C=C1)CC(N)(C(O)=O)CF
InChI
1S/C10H12FNO3/c11-6-10(12,9(14)15)5-7-1-3-8(13)4-2-7/h1-4,13H,5-6,12H2,(H,14,15)
InChI key
ACIQAJKTARSFHQ-UHFFFAOYSA-N
Biochem/physiol Actions
A racemic mixture of D- and L-AFMT. L-AFMT is reported to selectively inhibt against gut bacteria E. faecalis pyridoxal-5′-phosphate (PLP)-dependent tyrosine decarboxylase (TyrDC)-, but not aromatic amino acid decarboxylase (AADC)-, mediated L-dopa decarboxylation (IC50 = 4.7 μM/cell-free, 1.4 μM/in E. faecalis cultures; 20% human AADC inhibition at 650 μM) via covalent adduct formation with TyrDC co-factor PLP. When co-administered with L-dopa (10 mg/kg) and the AADC inhibitor carbidopa (30 mg/kg) to gnotobiotic mice colonized with E. faecalis, L-AFMT (25 mg/kg) significantly increases L-dopa peak serum concentration.
Covalent inhibtor against L-dopa decarboxylation by gut bacteria E. faecalis tyrosine decarboxylase (TyrDC), but not aromatic amino acid decarboxylase (AADC).
1 of 1
Questo articolo | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 200 | Quality Level 100 |
| storage temp. 2-8°C | storage temp. -10 to -25°C | storage temp. - | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear (warmed) | solubility 2 mg/mL, clear (0.1N HCl) | solubility 0.5 M HCl: 50 mg/mL | solubility DMSO: 2 mg/mL, clear |
| color white to beige | color white to beige | color white to off-white | color white to beige |
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Vayu Maini Rekdal et al.
Science (New York, N.Y.), 364(6445) (2019-06-15)
The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| SML3100-5MG | 04065266720914 |
| SML3100-25MG | 04065266720907 |



